title: Feasibility of intravenous administration of landiolol hydrochloride for multislice computed tomography coronary angiography: initial experience.
abstract: BACKGROUND
  The feasibility of using landiolol hydrochloride in multislice computed tomography (MSCT) coronary angiography (CAG) was investigated in the present study.
  
  
  RESULTS
  Landiolol hydrochloride was continuously administered intravenously to 145 patients before starting MSCT CAG. Hemodynamic changes [blood pressure (BP), heart rate (HR)], adverse effects, image quality using a 5-point scale, and accuracy of detecting significant stenoses (>or=50% reduction in lumen diameter) were evaluated. HR was significantly reduced during injection, and quickly recovered after cessation of administration, of landiolol hydrochloride. Neither significant changes in BP nor adverse effects occurred. Among visible segments, 1,869 (94%) displayed an excellent (83%) or good (11%) image quality. Diagnostic accuracy was evaluated in 39 of 145 patients who underwent invasive CAG within 3 weeks after MSCT. The sensitivity, specificity, positive predictive value, and negative predictive value of MSCT CAG for detection of significant stenoses in assessable segments were excellent (per artery: 94%, 98%, 92%, and 100%; per segment: 92%, 98%, 94%, and 96%, respectively).
  
  
  CONCLUSIONS
  Intravenous administration of landiolol hydrochloride reduces HR without a significant reduction in BP, which enables favorable image quality and diagnostic accuracy without adverse effects, making this agent feasible as a premedication for MSCT CAG.
authors.affiliation: Department of Cardiology, Kami-iida Daiichi General Hospital, Kita-machi, Kita-ku, Nagoya, Japan. sisobe@med.nagoya-u.ac.jp
authors.forename: Satoshi
authors.initials: S
authors.lastname: Isobe
authors.forename: Kimihide
authors.initials: K
authors.lastname: Sato
authors.forename: Kaichiro
authors.initials: K
authors.lastname: Sugiura
authors.forename: Takeo
authors.initials: T
authors.lastname: Mimura
authors.forename: Mikiko
authors.initials: M
authors.lastname: Kobayashi
authors.forename: Chizuka
authors.initials: C
authors.lastname: Meno
authors.forename: Makoto
authors.initials: M
authors.lastname: Kato
authors.forename: Hideki
authors.initials: H
authors.lastname: Ishii
authors.forename: Toyoaki
authors.initials: T
authors.lastname: Murohara
mesh_terms: D000368:Aged; D000889:Anti-Arrhythmia Agents / Q000494:pharmacology*; D001794:Blood Pressure / Q000187:drug effects; D017023:Coronary Angiography; D003324:Coronary Artery Disease / Q000000981:diagnostic imaging* / Q000503:physiopathology; D023921:Coronary Stenosis / Q000000981:diagnostic imaging* / Q000503:physiopathology; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D009025:Morpholines / Q000494:pharmacology*; D014057:Tomography, X-Ray Computed; D014508:Urea / Q000031:analogs & derivatives* / Q000494:pharmacology
chemical_list: D000889:Anti-Arrhythmia Agents; D009025:Morpholines; C077049:landiolol; D014508:Urea